Full Year Revenue and EPS Growth
For the full year 2024, revenue grew 21% and non-GAAP diluted EPS grew 32% from 2023 levels, driven by strength in MedTech and specialty audio.
Strong Cash Flow and Share Buyback Program
Generated $130 million in cash from operating activities for the full year 2024. The board authorized an additional $150 million in capacity for share repurchases.
Significant Order in the Energy Sector
Received an order for more than $75 million from a new customer in the energy sector, with at least $25 million of this order expected to ship in 2026.
Positive Book-to-Bill Trend in Precision Devices
The distribution book-to-bill trend was positive in Q4, with strong bookings in medical and defense markets.